Dr. Sebastian Beyer, LL.M. (Auckland)

Sebastian is a specialist in company law and capital market law. His clients primarily include listed companies and capital market-oriented corporations, investment banks, and other capital market participants.

Sebastian also advises executive boards and supervisory boards of listed companies on all legal and strategic matters.

CV

Since 2016 Salary Partner, Taylor Wessing

Since 2011 Associate, Taylor Wessing

2009 – 2011 Legal internship, Düsseldorf and Hong Kong

Career

Since 2016 Salary Partner, Taylor Wessing

Since 2011 Associate, Taylor Wessing

2009 – 2011 Legal internship, Düsseldorf and Hong Kong

Education

2008 – 2009 Doctoral degree, dissertation on the independence of supervisory board members under special consideration of US American law, University of Trier

2007 LL.M. with a focus on corporate law, University of Auckland (New Zealand)

2007 First state examination

Publications

#stayonboard – Das neue Recht auf Mandatspause, in: Der Betrieb, 09/2021

Aus AG wird N.V. – Der grenzüberschreitende Formwechsel einer deutschen AG in die Niederlande, in: AHA24x7, 09/2021

Nach der Krise ist vor der Krise - was müssen Vorstand und Aufsichtsrat eines Bundesligisten bei Transferentscheidungen beachten?, Audit Committee Quarterly, p. 28, 2020

Neue Grenzen bei der gerichtlichen Bestellung von Aufsichtsratsmitgliedern, in: NZG, 2014, p. 61

Aggressive Aktionäre als Reputationsrisiko, in: Börsen-Zeitung, 09/2014, p. 9, with Dr. Lars-Gerrit Lüßmann

Die Unabhängigkeit des Aufsichtsratsmitglieds unter besonderer Berücksichtigung des US-amerikanischen Rechts, Verlag Dr. Kovac, 2009

Additional languages

Awards

Legal 500 2025

Featured

Legal 500 Germany 2024

Legal 500 Germany 2023

Legal 500 Germany 2021/2022

Experience

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Press release

Dr. Sebastian Beyer, LL.M. (Auckland)

Tobias Kraut

Felipe Villena

Clemens Niedner

Prof. Dr. Michael Johannes Pils

Marcus Hartmann

Hauck & Aufhäuser

A Taylor Wessing team led by Frankfurt-based partners Lars-Gerrit Lüßmann and Ulrich Reers advised Hauck & Aufhäuser Investment Banking and Polish universal bank mBank in their role as exchange trustee and settlement agent on the voluntary public takeover/exchange offer by Frankfurt-listed Vita 34 AG, Leipzig, to the shareholders of Warsaw-listed stem cell bank Polski Bank Komórek Macierzystych S.A, Warsaw (PBKM). The transaction is the first cross-border exchange offer for a Polish listed company to date.

Press release

Jakub J. Pitera, Ph.D.

Dr. Sebastian Beyer, LL.M. (Auckland)

Patrycja Sojka

Marcus Hartmann

Rudi Hasenberg

Tobias Kraut

Eckert & Ziegler Strahlen- und Medizintechnik AG on its public takeover of the Belgian company Eckert & Ziegler BEBIG SA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a German FSE stock listed company on all aspects of a cross-border merger. Eckert & Ziegler Strahlen- und Medizintechnik AG, one of the world's largest suppliers of isotope technology components for radiation therapy and nuclear medicine with headquarters in Berlin, as absorbing entity merged with the Belgian Eckert & Ziegler BEBIG SA, which was listed on the Euronext Brussels stock exchange. The transaction is a rare example of cross-border mergers of two listed companies on the basis of the European harmonized requirements of the EU Company Directive (EU) 2017/1132.

Press release

Dr. Sebastian Buder

Thanos Rammos, LL.M.

Dr. Sebastian Beyer, LL.M. (Auckland)